Current Report Filing (8-k)
December 27 2018 - 3:13PM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
DC 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d)
of
the Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported)
December
26, 2018
OncBioMune
Pharmaceuticals, Inc.
(Exact
name of registrant as specified in its charter)
Nevada
|
|
000-52218
|
|
20-2590810
|
(State
or other jurisdiction
of
incorporation)
|
|
(Commission
File
Number)
|
|
(I.R.S.
Employer
Identification
No.)
|
11441
Industriplex Blvd, Suite 190., Baton Rouge, LA
|
|
70809
|
(Address
of principal executive offices)
|
|
(Zip
Code)
|
(225)
227-2384
(Registrant’s
telephone number, including area code)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
[ ]
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
[ ]
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
[ ]
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
[ ]
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Indicate
by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act
of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company [ ]
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [ ]
Item
5.02
|
Departure
of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain
Officers.
|
OncBioMune
Pharmaceuticals, Inc. (the “Company”) announces that Brian Barnett, MD, age 47, has been appointed as Chief Executive
Officer effective December 26, 2018. Dr. Barnett replaces Dr. Jonathan Head in this position. Dr. Head will continue to serve
the Company as the Chairman of the Board of Directors and now as its Chief Scientific Officer effective December 26, 2018. Prior
to joining the Company, Dr. Barnett served at Puma Biotechnology, Inc. since August 2016 (“Puma”) most recently as
a Vice President and Head of Medical Affairs. Prior to his time with Puma, Dr. Barnett was with Genentech, Inc., a subsidiary
of Roche, from October 2012 to August 2016 and served most recently as the Medical Director, Kadcyla (T-DM1), Global Product Development
Oncology. Prior to his appointment as CEO, Dr. Barnett was a member of our Scientific Advisory Board. Dr. Barnett received his
B.S. from Millsaps College and M.D. from the University of Mississippi.
The
Company and Dr. Barnett entered into an employment agreement effective December 26, 2018, which provided that Dr.
Barnett’s base salary would be $250,000 per year. Dr. Barnett is also eligible to receive a performance based bonus of
up to $150,000 upon completion of specific metrics established by the Company’s Board of Directors. Dr. Barnett is
entitled to participate in all medical and other benefits that the Company has established for its employees.
Upon
the effectiveness of Dr. Barnett’s employment agreement, he was granted options to purchase a number of shares of
the Company’s common stock equal to $100,000 divided by the volume weighted average price of the Company’s common
stock for the ten (10) business days prior to the effective date of the employment agreement. The option grant is subject to continued
employment, and will vest ratably over the first three anniversary dates of the grant date.
Additionally,
upon the closing of a transaction during calendar year 2019 which results in the sale of common stock of the Company on terms
acceptable to the Board that provides net proceeds to the Company of no less than $4,000,000 (a “Qualifying Transaction”),
Dr. Barnett shall be granted options to purchase a number of shares of the Company’s common stock equal to $50,000 divided
by the transaction price of the Company’s common stock in the Qualifying Transaction. The option grant is subject to continued
employment, and will vest ratably over the first three anniversary dates of the date of the closing of the Qualifying Transaction.
Dr.
Barnett does not have any family relationships with any of the Company’s other officers or directors.
The
Company intends to schedule an investor conference call to introduce Dr. Barnett which will be scheduled after the first of the
year.
This
information shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended
(the “Exchange Act”), or otherwise subject to the liabilities of that section, and it shall not be deemed incorporated
by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by
specific reference in such filing.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
OncBioMune
Pharmaceuticals
, INC.
|
|
|
|
|
By:
|
/s/
Andrew A. Kucharchuk
|
|
name
|
Andrew
A. Kucharchuk
|
|
position
|
President
and Chief Financial Officer
|
|
December
27, 2018
|
|